Stocktoria
Arcus Biosciences, Inc. RCUS
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2018-03-15
Arcus Biosciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $247.0M | $258.0M | $117.0M | $112.0M | $383.0M |
| R&D expense | $523.0M | $448.0M | $340.0M | $288.0M | $257.0M |
| Operating income | -$386.0M | -$330.0M | -$340.0M | -$280.0M | $54.0M |
| Income tax | $0 | $1.0M | $6.0M | $1.0M | $2.0M |
| Net income | -$353.0M | -$283.0M | -$307.0M | -$267.0M | $53.0M |
| EPS (diluted) | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.71 |
| Operating cash flow | -$482.0M | -$170.0M | -$306.0M | $438.0M | -$256.0M |
| Free cash flow | -$484.0M | -$176.0M | -$330.0M | $432.0M | -$282.0M |
| Cash & equivalents | $222.0M | $150.0M | $127.0M | $206.0M | $148.0M |
| Total assets | $1.1B | $1.1B | $1.1B | $1.3B | $1.6B |
| Total liabilities | — | — | — | — | $750.4M |
| Shareholders' equity | $631.0M | $485.0M | $462.0M | $657.0M | $842.0M |
Source: SEC EDGAR filings · CIK 0001724521 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.